Prognosis in patients with atrial fibrillation and CHA2DS2-VASc Score = 0 in a community-based cohort study

Sophie Taillandier; Jonas B Olesen; Nicolas Clémenty; Isabelle Lagrenade; Dominique Babuty; Gregory Y.H. Lip; Laurent Fauchier

doi:10.1111/j.1540-8167.2011.02257.x

Prognosis in patients with atrial fibrillation and CHA2DS2-VASc Score = 0 in a community-based cohort study

Sophie Taillandier, Jonas B Olesen, Nicolas Clémenty, Isabelle Lagrenade, Dominique Babuty, Gregory Y.H. Lip, Laurent Fauchier

42 Citationer (Scopus)

Abstract

Patients with atrial fibrillation (AF) and a CHA(2) DS(2) -VASc score = 0 have a very low risk of stroke and current guidelines even recommend no antithrombotic therapy to these patients. We investigated the rate and risk of adverse events and the impact of antithrombotic management in a community based cohort of AF patients with a CHA(2)DS(2)-VASc score = 0.

Originalsprog	Engelsk
Tidsskrift	Journal of Cardiovascular Electrophysiology
Vol/bind	23
Udgave nummer	7
Sider (fra-til)	708-13
Antal sider	6
ISSN	1045-3873
DOI	https://doi.org/10.1111/j.1540-8167.2011.02257.x
Status	Udgivet - 2012

Adgang til dokumentet

10.1111/j.1540-8167.2011.02257.x

Andre filer og links

Link to publication in Scopus

Citationsformater

@article{84f53e7afea94ea7aecb295817d95977,

title = "Prognosis in patients with atrial fibrillation and CHA2DS2-VASc Score = 0 in a community-based cohort study",

abstract = "Patients with atrial fibrillation (AF) and a CHA(2) DS(2) -VASc score = 0 have a very low risk of stroke and current guidelines even recommend no antithrombotic therapy to these patients. We investigated the rate and risk of adverse events and the impact of antithrombotic management in a community based cohort of AF patients with a CHA(2)DS(2)-VASc score = 0.",

keywords = "Adult, Age Factors, Aged, Anticoagulants, Atrial Fibrillation, Comorbidity, Decision Support Techniques, Diabetes Mellitus, Disease Progression, Disease-Free Survival, Evidence-Based Medicine, Female, Fibrinolytic Agents, France, Guideline Adherence, Heart Failure, Hemorrhage, Humans, Hypertension, Male, Middle Aged, Multivariate Analysis, Patient Selection, Platelet Aggregation Inhibitors, Practice Guidelines as Topic, Predictive Value of Tests, Proportional Hazards Models, Retrospective Studies, Risk Assessment, Risk Factors, Sex Factors, Stroke, Thromboembolism, Time Factors, Treatment Outcome",

author = "Sophie Taillandier and Olesen, \{Jonas B\} and Nicolas Cl{\'e}menty and Isabelle Lagrenade and Dominique Babuty and Lip, \{Gregory Y.H.\} and Laurent Fauchier",

note = "{\textcopyright} 2011 Wiley Periodicals, Inc.",

year = "2012",

doi = "10.1111/j.1540-8167.2011.02257.x",

language = "English",

volume = "23",

pages = "708--13",

journal = "Journal of Cardiovascular Electrophysiology",

issn = "1045-3873",

publisher = "John Wiley and Sons Inc.",

number = "7",

}

TY - JOUR

T1 - Prognosis in patients with atrial fibrillation and CHA2DS2-VASc Score = 0 in a community-based cohort study

AU - Taillandier, Sophie

AU - Olesen, Jonas B

AU - Clémenty, Nicolas

AU - Lagrenade, Isabelle

AU - Babuty, Dominique

AU - Lip, Gregory Y.H.

AU - Fauchier, Laurent

PY - 2012

Y1 - 2012

N2 - Patients with atrial fibrillation (AF) and a CHA(2) DS(2) -VASc score = 0 have a very low risk of stroke and current guidelines even recommend no antithrombotic therapy to these patients. We investigated the rate and risk of adverse events and the impact of antithrombotic management in a community based cohort of AF patients with a CHA(2)DS(2)-VASc score = 0.

AB - Patients with atrial fibrillation (AF) and a CHA(2) DS(2) -VASc score = 0 have a very low risk of stroke and current guidelines even recommend no antithrombotic therapy to these patients. We investigated the rate and risk of adverse events and the impact of antithrombotic management in a community based cohort of AF patients with a CHA(2)DS(2)-VASc score = 0.

KW - Adult

KW - Age Factors

KW - Aged

KW - Anticoagulants

KW - Atrial Fibrillation

KW - Comorbidity

KW - Decision Support Techniques

KW - Diabetes Mellitus

KW - Disease Progression

KW - Disease-Free Survival

KW - Evidence-Based Medicine

KW - Female

KW - Fibrinolytic Agents

KW - France

KW - Guideline Adherence

KW - Heart Failure

KW - Hemorrhage

KW - Humans

KW - Hypertension

KW - Male

KW - Middle Aged

KW - Multivariate Analysis

KW - Patient Selection

KW - Platelet Aggregation Inhibitors

KW - Practice Guidelines as Topic

KW - Predictive Value of Tests

KW - Proportional Hazards Models

KW - Retrospective Studies

KW - Risk Assessment

KW - Risk Factors

KW - Sex Factors

KW - Stroke

KW - Thromboembolism

KW - Time Factors

KW - Treatment Outcome

UR - https://www.scopus.com/pages/publications/84861737050

U2 - 10.1111/j.1540-8167.2011.02257.x

DO - 10.1111/j.1540-8167.2011.02257.x

M3 - Journal article

C2 - 22268375

SN - 1045-3873

VL - 23

SP - 708

EP - 713

JO - Journal of Cardiovascular Electrophysiology

JF - Journal of Cardiovascular Electrophysiology

IS - 7

ER -

Prognosis in patients with atrial fibrillation and CHA2DS2-VASc Score = 0 in a community-based cohort study

Abstract

Adgang til dokumentet

Andre filer og links

Fingeraftryk

Citationsformater